Search Results

You are looking at 1 - 10 of 76 items for :

  • "pleural effusion" x
  • Refine by Access: All x
Clear All
Full access

Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102)

Todd L. Demmy, Lin Gu, Jack E. Burkhalter, Eric M. Toloza, Thomas A. D'Amico, Susan Sutherland, Xiaofei Wang, Laura Archer, Linda J. Veit, Leslie Kohman, and the Cancer and Leukemia Group B

Approximately 100,000 new malignant pleural effusions (MPEs) occur annually in the United States, adversely affecting quality of life (QOL), often within months of death. 1 , 2 Optimal palliative management of these symptomatic patients is still

Full access

CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non–Small Cell Lung Cancer

John Sharp, Daniel Jones, Julia Rotow, Panos Fidias, Erin Bertino, and Dwight Owen

malignant ascites. Testing of her ascites fluid confirmed mNSCLC with BRAF p.N486_N490del. Off-label dab/tram were obtained through a Novartis assistance program. Staging CT scans prior to dab/tram showed numerous pulmonary masses, a pleural effusion

Full access

Malignant Pleural Mesothelioma

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary Pinder Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang

form without the express written permission of NCCN®. Diagnosis Patients with suspected MPM often have symptoms (e.g., dyspnea and chest pain) and can also have pleural effusion, cough, chest wall mass, weight loss, fever, and sweating

Full access

Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer

John A. Sharp, Daniel Jones, Julia K. Rotow, Panos M. Fidias, Erin Bertino, and Dwight H. Owen

the lung developed new malignant ascites while receiving treatment with third-line docetaxel. She had been diagnosed with stage IV NSCLC one year prior after being found to have a malignant pleural effusion. At that time, her tumor cells were noted to

Full access

A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK

Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, and Haibo Zhang

amount of pleural effusion. (C1–C3) CT shows partial response after 8 weeks of alectinib. (D1–D3) CT shows continuous response when taking alectinib for 6 months. Figure 2. A fusion variant of EML4 intron 6 with ALK intron 17 was

Full access

Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients

Chloe E. Atreya, Eric A. Collisson, Meyeon Park, James P. Grenert, Spencer C. Behr, Amalia Gonzalez, Jonathan Chou, Samantha Maisel, Terence W. Friedlander, Chris E. Freise, Jun Shoji, Thomas J. Semrad, Jessica Van Ziffle, and Peter Chin-Hong

imaging with hypermetabolic supraclavicular, mediastinal (B), and abdominal lymph nodes and foci in left femoral neck and right ilium. Imaging also visualized diffuse anasarca with pericardial and pleural effusions, hepatic congestion, and small ascites

Full access

Randomized Controlled Trials and 21st Century Epistemology

Frederic W. Grannis Jr

responsible in candidly discussing these weaknesses. The concern, however, is that those gathering evidence and writing guidelines on the subject of malignant pleural effusions at some later date, who will typically not have substantial clinical experience

Full access

How to Choose Frontline Therapy for Chronic Myelogenous Leukemia: So Many Drugs, Not So Many Patients

Paul J. Shami

. Thrombocytopenia was more common with dasatinib, whereas neutropenia occurred at equal frequency. Edema, nausea, vomiting, and rashes were more common with imatinib. In earlier studies, pleural effusions were seen in patients treated with dasatinib, particularly at

Full access

Optimizing Patient Care in Chronic Phase Chronic Myelogenous Leukemia: A Multidisciplinary Approach

Hema Sundar and Jerald Radich

taking antacids while on dasatinib due to potential drug-drug interactions and was also made aware of the common adverse events associated with dasatinib (eg, peripheral edema and pleural effusion). She was also asked to notify the doctor immediately if

Full access

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

with suspected MPM often have dyspnea and chest pain; they may also have pleural effusion, fatigue, insomnia, cough, chest wall mass, loss of appetite, and weight loss. 14 – 16 Patients with MPM often have a high symptom burden; therefore, supportive